H. Evin Gulbahce, MD, MSCI

Professor, University of Utah School of Medicine

Specialties

• Breast pathology
• FISH

Education

• Medical Degree—Hacettepe University School of Medicine
• Residency—Anatomic and Clinical Pathology, University of Minnesota
• Fellowship—Surgical Pathology, University of Minnesota
• MS Clinical Investigation—University of Utah

Certification/Affiliations

• American Board of Pathology

Research Interests

• Breast cancer risk factors, specifically for basal-like and triple-negative breast cancers
• HER2 testing

Awards

• Clinical Excellence, Department of Pathology, University of Utah
• Outstanding Teaching Award, Department of Pathology, University of Utah

Recent Publications

• Balatico M, Ruano AL, Cleary AS, et al. Male invasive lobular breast cancer: clinicopathologic features including recurrence score results from a population-based database. Arch Pathol Lab Med. 2024;148(3):263-264.
• Wilcock D, Sirohi D, Albertson D, et al. Clinicopathologic features of breast carcinoma with 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 (human epidermal growth factor receptor 2 chromosome 17 centromere ratio <2.0 and average human epidermal growth factor receptor 2 copy number ≥6.0) breast cancers. Arch Pathol Lab Med. 2023 Published online Nov 2023. 
• McMurtry V, Cleary AS, Ruano AL, et al. Metaplastic breast carcinoma: clinicopathologic features and recurrence score results from a population-based database. Am J Clin Oncol. 2023;46(12):559-566.
• Wilcock DM, Moore KH, Rowe L, et al. Quantitative imaging analysis fluorescence in situ hybridization validation for clinical HER2 testing in breast cancer. Arch Pathol Lab Med. 2023;147(12):1402-1412.
• Wilcock DM, McMurtry V, Coleman JF, et al. Histopathological correlation of chromosome 12 polysomy by fluorescence in situ hybridization in adipocytic neoplasms. Int J Surg Pathol. 2022;30(7):734-742.
• Wilcock DM, Sirohi D, Coleman JF, et al. Digital imaging correlation of immunohistochemistry and fluorescence in situ hybridization in breast carcinoma cases with HER2 genetic heterogeneity. 2022;126:129-135.
• Jedrzkiewicz J, Sirohi D, Uvejzovic N, et al. RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory. Mod Pathol. 2022;35(4):549-553.
• Gulbahce HE, Downs-Kelly E, Herget KA, et al. The 21-gene recurrence score in special histologic subtypes of breast cancer: a population-based study. Arch Pathol Lab Med. 2022;146(4):478-484.
• Mahlow J, Goold E, Jedrzkiewicz J, et al. What to expect from the new ASCO/CAP guideline recommendations for hormone receptor testing in breast cancer: a national reference laboratory experience. Appl Immunohistochem Mol Morphol. 2021;29(4):245-250.
• Gulbahce HE, White S, Herget KA, et al. 21-gene recurrence score testing utilization among older women from different races: a population-based study. Journal of Geriatric Oncology. 2021;12:206-211.
• Gulbahce HE, Coleman JF, Sirohi D. Interference of tissue-marking dyes with fluorescent in situ hybridization assays. Arch Pathol Lab Med. 2019;143(11):1299.
• Lin L, Sirohi D, Coleman JF, et al. American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2018 focused update of breast cancer HER2 FISH testing guidelines: results from a national reference laboratory. Am J Clin Pathol. 2019;152(4):479-485.
• Schneider F, Jin Y, Van Smaalen K, et al. The FDA-approved breast cancer HER2 evaluation kit (HercepTest; Dako) may miss some HER2-positive breast cancers. Am J Clin Pathol. 2019;151(5):504-510.